301075 多瑞医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.869-16.331-8.6512.4752.655
总资产报酬率 ROA (%)0.889-7.251-4.8071.9132.343
投入资产回报率 ROIC (%)1.313-10.734-6.2932.0742.449

边际利润分析
销售毛利率 (%)11.2048.17342.41568.55276.981
营业利润率 (%)4.928-83.264-35.6416.6375.300
息税前利润/营业总收入 (%)13.478-74.293-34.3055.2953.316
净利润/营业总收入 (%)3.388-85.877-35.3355.1134.634

收益指标分析
经营活动净收益/利润总额(%)-673.07691.45087.82616.70859.917
价值变动净收益/利润总额(%)643.498-0.678-6.84725.6620.054
营业外收支净额/利润总额(%)24.5542.2710.0100.277-1.101

偿债能力分析
流动比率 (X)0.6610.7441.2385.0244.478
速动比率 (X)0.4400.5551.1484.7674.252
资产负债率 (%)46.57851.40850.91323.37016.182
带息债务/全部投入资本 (%)11.45119.38221.29819.27812.196
股东权益/带息债务 (%)651.664339.653308.203416.939719.075
股东权益/负债合计 (%)108.08287.09086.592308.101516.675
利息保障倍数 (X)1.940-6.812-25.609-3.893-1.722

营运能力分析
应收账款周转天数 (天)169.954213.640136.61591.08884.255
存货周转天数 (天)202.831164.504102.593112.82583.045